These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 9439500)

  • 1. Losartan and renal transplantation.
    Horn S; Holzer H; Horina J
    Lancet; 1998 Jan; 351(9096):111. PubMed ID: 9439500
    [No Abstract]   [Full Text] [Related]  

  • 2. Losartan and renal transplantation.
    Aurup P; Smith RD
    Lancet; 1998 Mar; 351(9107):990. PubMed ID: 9734972
    [No Abstract]   [Full Text] [Related]  

  • 3. Fetal toxic effects and angiotensin-II-receptor antagonists.
    Martinovic J; Benachi A; Laurent N; Daikha-Dahmane F; Gubler MC
    Lancet; 2001 Jul; 358(9277):241-2. PubMed ID: 11480433
    [No Abstract]   [Full Text] [Related]  

  • 4. Efficacy and safety of losartan in renal transplant recipients.
    Hadjigavriel M; Kyriakides G
    Transplant Proc; 1999 Dec; 31(8):3300-1. PubMed ID: 10616484
    [No Abstract]   [Full Text] [Related]  

  • 5. Blockade of angiotensin II AT 1 receptor reduces hematocrit in patients with posttransplant erythrocytosis.
    Tsang WK; Tong KL; Chan HW
    Transplant Proc; 1998 Nov; 30(7):3072-3. PubMed ID: 9838354
    [No Abstract]   [Full Text] [Related]  

  • 6. Angiotensin II type 1 (AT1) receptor antagonists in the treatment of hypertension after renal transplantation.
    Holgado R; Anaya F; Del Castillo D
    Nephrol Dial Transplant; 2001; 16 Suppl 1():117-20. PubMed ID: 11369838
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term anti-proteinuric effect of Losartan in renal transplant recipients treated for hypertension.
    Calviño J; Lens XM; Romero R; Sánchez-Guisande D
    Nephrol Dial Transplant; 2000 Jan; 15(1):82-6. PubMed ID: 10607772
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of angiotensin converting enzyme inhibitor and angiotensin II receptor antagonist therapy in hypertensive renal transplant recipients.
    Kim W; Lee S; Kang SK; Yu HC; Cho BH; Park SK
    Transplant Proc; 2002 Dec; 34(8):3223-4. PubMed ID: 12493427
    [No Abstract]   [Full Text] [Related]  

  • 9. Is it time for ACE inhibitors in chronic allograft nephropathy?
    Lewis JB; Helderman JH
    Am J Kidney Dis; 2000 Jan; 35(1):154-6. PubMed ID: 10620559
    [No Abstract]   [Full Text] [Related]  

  • 10. Treatment of moderate or severe arterial hypertension with losartan.
    Dimitrova A; Todorova M; Bianov K; Halachev N; Dineva S; Elenkova A
    Folia Med (Plovdiv); 1998; 40(3B Suppl 3):43-5. PubMed ID: 10205992
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparative study of losartan and enalapril on erythropoiesis and renal function in hypertensive patients with renal parenchymal disease.
    Shand BI; Lynn KL
    Clin Nephrol; 2000 Nov; 54(5):427-8. PubMed ID: 11105808
    [No Abstract]   [Full Text] [Related]  

  • 12. Efficacy and tolerability of fimasartan, a new angiotensin receptor blocker, compared with losartan (50/100 mg): a 12-week, phase III, multicenter, prospective, randomized, double-blind, parallel-group, dose escalation clinical trial with an optional 12-week extension phase in adult Korean patients with mild-to-moderate hypertension.
    Lee SE; Kim YJ; Lee HY; Yang HM; Park CG; Kim JJ; Kim SK; Rhee MY; Oh BH;
    Clin Ther; 2012 Mar; 34(3):552-568, 568.e1-9. PubMed ID: 22381711
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Losartan].
    Quetglas EG; Sádaba B; Escolar M; Honorato J
    Rev Med Univ Navarra; 1997; 41(3):193-7. PubMed ID: 10420926
    [No Abstract]   [Full Text] [Related]  

  • 14. Losartan and hypertensive children. Another option for a small number of children.
    Prescrire Int; 2010 Aug; 19(108):160. PubMed ID: 20939445
    [No Abstract]   [Full Text] [Related]  

  • 15. [Losartan potassium, an angiotensin II receptor antagonist].
    Yoshinaga K
    Nihon Rinsho; 2000 Feb; 58 Suppl 2():140-3. PubMed ID: 11028309
    [No Abstract]   [Full Text] [Related]  

  • 16. [Reduction of cardiovascular events with lorsartan? The LIFE Study].
    Schunkert H
    Internist (Berl); 2003 Mar; 44(3):367-70. PubMed ID: 12731424
    [No Abstract]   [Full Text] [Related]  

  • 17. Anemia due to losartan in hypertensive renal transplant recipients without posttransplant erythrocytosis.
    Ersoy A; Kahvecioglu S; Ersoy C; Cift A; Dilek K
    Transplant Proc; 2005 Jun; 37(5):2148-50. PubMed ID: 15964363
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [AT1 receptor antagonist lorsartan and organ protection. Managing hypertension a different way].
    MMW Fortschr Med; 2006 Mar; 148(13):48-9. PubMed ID: 16642707
    [No Abstract]   [Full Text] [Related]  

  • 19. Angiotensin-converting enzyme inhibitors but not angiotensin II AT 1 receptor antagonists affect erythropoiesis in patients with anemia of end-stage renal disease.
    Schiffl H; Lang SM
    Nephron; 1999 Jan; 81(1):106-8. PubMed ID: 9884431
    [No Abstract]   [Full Text] [Related]  

  • 20. [Young patient with mild hypertension: angiotensin inhibitor or beta blocker?].
    Girndt M
    MMW Fortschr Med; 2011 Sep; 153(38):17. PubMed ID: 21977791
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.